EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder

Garth T Whiteside iD, Ellie He, Manjunath S Shet, Mingyan Zhou, Maha Ahmad, Stephen C Harris

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70193 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Garth T Whiteside und 5 weiteren Autor:innen. Beteiligte Einrichtung: Imbrium Therapeutics, Stamford, CT, USA. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Receptors, Opioid, Hypnotics and Sedatives. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Imbrium Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Insomnia is a common sleep disorder, affecting up to 20% of the world population and adversely impacting productivity, health, and overall well‐being. Although pharmacologic options exist to treat insomnia, the health‐related quality of life for patients who are prescribed hypnotics is no higher than for those who are not, revealing a significant treatment gap. Sunobinop, an oral, selective, potent, partial agonist of the nociceptin receptor (NOP), was evaluated for efficacy and safety in the treatment of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) insomnia disorder.

Methods

In this randomized, double‐blind, repeat‐dose, crossover, Phase 1 study, 30 patients were assigned to treatment with sunobinop 0.5 mg, 1.0 mg, 3.0 mg and 6.0 mg and placebo; changes in sleep parameters, measured by polysomnography (PSG), in addition to subjective sleep measures and safety‐related measures were assessed. Twenty‐nine patients completed the study.

Results

Sunobinop demonstrated a dose‐dependent and significant increase in sleep efficiency compared with placebo. Sleep efficiency was statistically significantly increased by 12.1%, 14.7%, 17.6% and 19.0% over baseline at 0.5 mg, 1.0 mg, 3.0 mg and 6.0 mg, respectively ( P ≤ 0.001) compared to placebo. Sunobinop improved sleep maintenance, measured by wakefulness after sleep onset, at all doses compared with placebo. Sunobinop resulted in a significant dose‐dependent change in time spent in N1 and N2 sleep with no effect on rapid eye movement (REM) latency, differentiating sunobinop from other hypnotics. Results from PSG measures correlated well with those from subjective assessments. Adverse events (AEs) that occurred in this study were rated by investigators as largely mild.

Conclusions

In this Phase 1 study of 30 patients, sunobinop was well tolerated by patients, with no study discontinuation due to AEs. Doses were identified that had a beneficial effect on sleep measures without eliciting next‐day residual effects (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Initiation and Maintenance DisordersReceptors, OpioidHypnotics and SedativesHumansMaleFemaleDouble-Blind MethodCross-Over StudiesAdultMiddle AgedDose-Response Relationship, DrugNociceptin ReceptorTreatment OutcomePolysomnographyYoung AdultSleepAged

Stichwörter der Autor:innen

NOPinsomnianociceptin/orphanin FQpolysomnographysleep efficiencysunobinop

Substanzen

Receptors, OpioidNociceptin ReceptorOPRL1 protein, humanHypnotics and Sedatives

Autor:innen und Institutionen

  • Imbrium Therapeutics, Stamford, CT, USA.
  • Sleep Disorders Institute, New York, NY, USA.
  • Clinilabs Drug Development Corporation, New York, NY, USA.

ORCID-Profile: Garth T Whiteside

Förderung

  • Imbrium Therapeutics

Zitieren

APA

Whiteside, G. T., He, E., Shet, M. S., Zhou, M., Ahmad, M., & Harris, S. C. (2026). Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70193

Vancouver

Whiteside GT, He E, Shet MS, Zhou M, Ahmad M, Harris SC. Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70193

BibTeX
@article{Whiteside2026,
  author = {Whiteside, Garth T and He, Ellie and Shet, Manjunath S and Zhou, Mingyan and Ahmad, Maha and Harris, Stephen C},
  title = {Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70193}
}
Kostenlos starten →